Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Monday, 14 July 2025 12:00 AM EOD	Adani-Ports1433.30	Asian-Paints2401.00	Axis-Bank1173.45	Bajaj-Finance918.95	Bajaj-Finserv2003.65	Bharat-Electron407.35	Bharti-Airtel1922.45	Eternal-Ltd270.75	HCL-Technologies1619.95	HDFC-Bank1983.00	Hind-Unilever2516.25	ICICI-Bank1422.75	Infosys1570.45	ITC419.30	Kotak-Mah-Bank2203.30	Larsen-and-Toubro3496.15	M-and-M3090.90	Maruti-Suzuki12515.50	NTPC341.95	Power-Grid-Corpn298.20	Reliance-Industr1484.60	St-Bk-of-India809.30	Sun-PharmaInds1682.05	Tata-Motors674.50	Tata-Steel160.35	TCS3223.20	Tech-Mahindra1578.15	Titan-Company3405.85	Trent5313.90	UltraTech-Cem12513.10
15 mins delay SENSEX 82,253.46 [-247.01]	2.65 0.19%	-38.60 -1.58%	-0.30 -0.03%	-14.40 -1.54%	-12.80 -0.63%	-1.90 -0.46%	0.55 0.03%	7.45 2.83%	-17.05 -1.04%	-0.55 -0.03%	-3.85 -0.15%	0.55 0.04%	-24.45 -1.53%	2.25 0.54%	-16.50 -0.74%	-44.40 -1.25%	15.95 0.52%	-62.00 -0.49%	-0.60 -0.18%	-0.40 -0.13%	-10.25 -0.69%	0.80 0.10%	9.55 0.57%	-7.10 -1.04%	0.50 0.31%	-42.20 -1.29%	-24.85 -1.55%	46.90 1.40%	-38.50 -0.72%	19.35 0.15%

Hot Pursuit

Scrips, which has significant changes during the market hours.

Wockhardt climbs on exiting US generics to refocus on innovation

14-Jul-25 17:12Hrs IST

The move is aimed at realigning focus toward high-impact areas, including novel antibiotic drug discovery and biologics-led insulin solutions.

The decision comes after its US generics unit posted a $8 million loss in FY25. To facilitate the exit, Wockhardt filed for voluntary liquidation of its US subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, under Chapter 7 of the US Bankruptcy Code, effective 11 July 2025.

The company says this decision enables a clean and structured exit from a legacy segment and unlocks management bandwidth and capital for high-impact areas. The company remains committed to its pharmaceutical operations in India, the UK, Ireland, and other geographies where its businesses continue to deliver strong performance.

Wockhardt is a research based global pharmaceutical and biotech company. On a consolidated basis, Wockhardt reported net loss of Rs 25 crore in Q4 March 2025 as against net loss of Rs 169 crore in Q4 March 2024. Net sales rose 6.14% YoY to Rs 743 crore in Q4 March 2025.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

A Muthoot M George Enterprise